Welcome Visitor,
Please Login or Register



This Sample test is for your own personal assessment, and is identical to the CEUS test. You may take the test and receive results. However, you will not be given credit until completing the CEUS Test. There is no charge for taking the CEUS test. After passing the CEUS test, you may pay to receive a certificate of completion. Any post-test that you have passed will be listed on your Member Account page.

Fill in the form below and click the submit button to complete your test.

45 questions have been provided. You must answer 80% correctly to pass.

 

Print

Medications for Opioid Use Disorder
1)

According to SAMHSA and NIDA, opioid addiction is best understood as:
 
A temporary habit A personal weakness A short-term illness A chronic, treatable illness
 
2)

What has been shown to improve retention and outcomes for people with OUD?
 
Short inpatient detox only Prayer and meditation alone Ongoing outpatient medication treatment Avoiding all formal treatment
 
3)

Methadone treatment is supported by:
 
A large, global evidence base Anecdotal reports only One small clinic trial No scientific studies
 
4)

How should providers decide when to discontinue OUD medication?
 
Set the same time limit for all Follow insurance company rules Use evidence, assessment, and collaborative planning Stop after three months automatically
 
5)

Why is medically supervised withdrawal required before starting naltrexone?
 
Naltrexone is addictive It blocks all withdrawal symptoms It requires a period without opioids It works only with methadone
 
6)

What major policy change did SAMHSA implement in 2024 regarding opioid treatment programs (OTPs)?
 
Eliminated all OTPs Increased barriers to care Banned telehealth use for MOUD Revised 42 CFR Part 8 to modernize and expand access
 
7)

If a provider does not offer medication for OUD, what is the priority?
 
Delay diagnosis until referral Provide no intervention Avoid discussing substance use Ensure diagnosis, safety, and referral
 
8)

Why is assessing for comorbid mental illness important in patients with OUD?
 
It is usually rare It prevents relapse completely It complicates treatment and worsens prognosis It eliminates the need for medication
 
9)

Why is gathering social history important in OUD treatment planning?
 
It replaces medical treatment It prevents withdrawal symptoms It helps guide treatment engagement, retention, and prognosis It eliminates the need for medications
 
10)

What does the severity of opioid withdrawal help determine?
 
Employment readiness Level of dependence and dosing needs Housing stability Risk of HIV infection
 
11)

A negative opioid test without withdrawal symptoms most likely indicates:
 
Severe dependence Recent binging Assay detects all Little or no tolerance
 
12)

When may family members be included in treatment planning?
 
Always, without exception Only if legally required With the patient’s consent Never under any circumstances
 
13)

At the start of methadone treatment in an OTP, how often must patients typically visit?
 
Once a month Twice a week 6 to 7 times per week Only as needed
 
14)

Which patients may be appropriate candidates for residential treatment?
 
Those with no substance issues Only patients with mild OUD Patients with OUD, other SUDs, or unstable living situations Only patients who refuse medication
 
15)

What types of services may support patients receiving OUD medication?
 
Only medical checkups Counseling, peer support, and case management Gym memberships only None beyond medication
 
16)

What should providers understand about relapse during recovery?
 
It means treatment has failed Patients never try again It is an expected part of the process It eliminates future recovery chances
 
17)

What have short-term pilot studies shown about offering XR-NTX before release from controlled environments?
 
It eliminates relapse completely It prevents all withdrawal symptoms It increases treatment engagement after release It is less effective than no treatment
 
18)

Which option can relieve some withdrawal symptoms when opioid agonist medications are unavailable?
 
Ibuprofen Clonidine Naloxone Acetaminophen
 
19)

Which methadone formulation is most commonly used in treatment programs?
 
Tablets Liquid concentrate Powder capsules Inhaled spray
 
20)

When do patients typically feel the full effect of their methadone dose?
 
Same day Next morning After 4 or more days After 2 hours
 
21)

What safety advice should be given to patients beginning methadone treatment?
 
Avoid eating after doses Exercise daily Be cautious with driving and heavy machinery Increase caffeine intake
 
22)

Which reproductive-related side effect may occur with methadone use?
 
Fertility increase Amenorrhea or decreased libido Enhanced sexual function Early menopause
 
23)

During the first 90 days of OTP treatment, how many take-home doses are typically allowed per week?
 
None One, with possible increase to two Five Unlimited
 
24)

What is the generally recommended safety limit for the first day’s methadone dosing?
 
30 mg 10 m 50 mg 5 mg
 
25)

Which factor would OTP medical directors consider before approving take-home doses?
 
Patient’s clothing style Safe storage ability and treatment stability Number of siblings Favorite counseling method
 
26)

Who should be tested annually for hepatitis C?
 
Only patients over 65 People who use drugs by injection Patients who exercise daily Only those in remission
 
27)

Which group is not an appropriate candidate for XR-NTX treatment?
 
Men over 40 Adolescents Pregnant women Patients with anxiety
 
28)

Why might some patients stop using illicit opioids after starting XR-NTX?
 
It causes withdrawal It makes opioids stronger It increases cravings It blocks the euphoric effects
 
29)

Why should unstable patients be discouraged from stopping treatment?
 
They may lose insurance High relapse and overdose risk It prevents employment They won’t qualify for counseling
 
30)

When should patients take their first buprenorphine dose during home induction?
 
Immediately after opioid use When withdrawal begins, at least 12 hours after last short-acting opioid Exactly 24 hours after any opioid Before any withdrawal occurs
 
31)

What is the primary goal of buprenorphine treatment?
 
Short detox Full remission Dose reduction Rapid taper
 
32)

How should treatment success be measured?
 
Progress on agreed goals Dose size Length of treatment Medication brand
 
33)

Why is adequate pain management important in patients with OUD?
 
To shorten hospital stay Poor pain control may trigger relapse To lower medication costs To reduce counseling needs
 
34)

Can pregnant women on buprenorphine continue the medication during labor?
 
No Yes Only with taper Only after delivery
 
35)

How does the American Society of Addiction Medicine define addiction?
 
A moral failing A short habit A chronic brain disease A legal issue
 
36)

Which of the following is a key feature of OUD per DSM-5?
 
Loss of control, risky use, and social impairment Perfect control of use Only physical injury Lack of tolerance or withdrawal
 
37)

Why are longer courses of OUD medication beneficial?
 
They prevent hospital visits They allow stabilization and healthy lifestyle building They cure OUD quickly They avoid counseling needs
 
38)

Which of the following is an example of building recovery capital?
 
Isolating from others Forging supportive relationships Avoiding employment Ignoring coping skills
 
39)

What is a key feature of trauma-informed care?
 
Ignoring trauma history Focusing only on medications Recognizing trauma signs and avoiding retraumatization Limiting care to policies
 
40)

What happens in the brain when opioids activate receptors and the nucleus accumbens (NAc)?
 
No change occurs Dopamine is released, causing euphoria Endorphins stop working The reward system shuts down
 
41)

Why do environmental cues become triggers for drug use?
 
The brain links them with dopamine release and euphoria They reduce cravings They block opioid receptors They erase memory of use
 
42)

Who is especially at risk of methadone overdose?
 
Long-term patients People new to opioids or recently abstinent Those on buprenorphine Patients in OTPs only
 
43)

When do patients typically begin buprenorphine treatment?
 
After full detox During opioid withdrawal After a month of abstinence Only in residential care
 
44)

What can prescribers do if XR-NTX effectiveness declines before the next dose?
 
Increase the dose Stop treatment Shorten the dosing interval Add a second injection
 
45)

What strategy can encourage patients to return to treatment after relapse?
 
Ignoring them Offering expedited reentry and active outreach Punishing with longer waits Canceling their records
 

 
 

© 2005 - 2025 Speedy Ceus®. All rights reserved. A CE Provider.

Privacy Policy